 |
SYDNEY, Nov. 11, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that PNOC022 (NCT05009992), a multi-drug phase II study in DIPG and diffuse midline gliomas, has been initiated at the University of California, San Francisco, with the first patient...
Andrew North joins the Icon Agency team, bringing three decades of senior creative experience to further bolster the agency’s integrated offering. Icon Agency welcomes Andrew North - more commonly known as Northy - as Creativ...
Australian small businesses are battling with billions in outstanding invoices, according to Debtplacer, a platform that connects businesses with a marketplace of debt collectors and law firms. According to a government repor...
Dyson engineers are working on a new generation of intelligent, self-improving, connected products, as the company builds up its software-based team, Jake Dyson, Chief Engineer, reveals in a new Dyson YouTube video. He says th...